505 Low one-year mortality in chronic heart failure in a hybrid service with a clinic-based follow-up plus hospital readmission: Role of quality of life and distress assessment

2003 ◽  
Vol 2 (1) ◽  
pp. 102-103
Author(s):  
G CARBONI ◽  
C GOFFREDO
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Chronic Heart Failure ◽  
Hospital Readmission ◽  
One Year

scholarly journals Quality of life in patients with chronic heart failure and their carers: a 3-year follow-up study assessing hospitalization and mortality

2010 ◽  
Vol 12 (9) ◽  
pp. 1002-1008 ◽  
Author(s):  
Javaid Iqbal ◽  
Loraine Francis ◽  
Janet Reid ◽  
Scott Murray ◽  
Martin Denvir
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Chronic Heart Failure ◽  
Follow Up Study

071 Quality of life in patients with chronic heart failure and their carers: a 3-year follow-up study assessing hospitalisation and mortality

Heart ◽  
2010 ◽  
Vol 96 (Suppl 1) ◽  
pp. A41-A41
Author(s):  
J Iqbal ◽  
L Francis ◽  
J Reid ◽  
S Murray ◽  
MA Denvir
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Chronic Heart Failure ◽  
Follow Up Study

THE ROLE OF SCHOOL HEALTH IN IMPROVING THE QUALITY OF LIFE IN PATIENTS WITH CHRONIC HEART FAILURE

2019 ◽  
Vol 1 ◽  
pp. 5-11
Author(s):  
D.S. PONOMAREV ◽  
◽  
S.N. SIMONOV ◽  
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Chronic Heart Failure ◽  
School Health

Ivabradine effects on heart rate and quality of life among chronic heart failure patients

2020 ◽  
pp. 1-12
Author(s):  
Fawad Farooq ◽  
Nida Imran ◽  
Mahwish Abbas
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Heart Rate ◽  
Chronic Heart Failure ◽  
Health Related Quality ◽  
Heart Failure Patients ◽  
Related Quality ◽  
Health Related

Abstract Objective: To determine the effect of Ivabradine in lowering heart rate and quality of life in chronic heart failure patients. Methods: The observational study was conducted in the out-patient department of the National Institute of Cardiovascular Disease, Karachi, from December 2016 to June 2017, and comprised chronic heart failure patients aged 30-70 years who were on 5mg Ivabradine for 8-weeks. Heart rate was evaluated through electrocardiogram, and health-related quality of life was measured using the validated questionnaire. Baseline demographics and clinical characteristics were recorded, with follow-ups at week-4 and week-8. Safety and tolerability were assessed by adverse drug reactions monitoring. Data was analysed using SPSS 21. Results: Of the 50 patients, 34(68%) were males. The overall mean age was 54.8±9.17 years. Baseline mean heart rate significantly reduced at first and second follow-up visit (p< 0.001). Mobility problems declined significantly as well (p<0.05). Health-related quality of life significantly improved on follow-up visits (p<0.001). Conclusion: There was significant control of heart rate in chronic heart failure patients with improvement in all parameters of quality of life. Key Words: Heart failure, Ivabradine, Heart rate, Continuous...

CURRENT ASPECTS OF DRUG THERAPY OF CHRONIC HEART FAILURE SYNDROME

2020 ◽  
Vol 4 (2) ◽  
pp. 1085-1096
Author(s):  
T.V. Statkevich ◽  
◽  
N.P. Mitkovskaya ◽  
◽  
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Drug Therapy ◽  
Chronic Heart Failure ◽  
Clinical Symptoms ◽  
Nyha Class ◽  
Treatment And Prevention ◽  
One Year ◽  
The One

Chronic heart failure (CHF) is an important problem for the country, which has both medical and socio-economic aspects. The presence of the syndrome not only significantly increases the risks of an unfavorable course of diseases underlying its etiological basis, but in itself, through the development of decompensation, causes a high frequency of deaths. Despite all the advances in pharmacotherapy, the prognosis of heart failure remains poor. More than 40% of patients die within 4 years after the diagnosis of heart failure, and the one-year mortality rate for patients with severe CHF (NYHA class IV) exceeds 50%. The foregoing determines the need and importance of using all possible drug and non-drug therapy technologies aimed at reducing mortality, increasing the duration and quality of life of patients with CHF, as well as reducing the number and likelihood of decompensation and related hospitalizations, and makes this direction one of the priorities in medicine. The article describes current approaches to the treatment of patients with CHF syndrome from the perspective of evidence-based medicine and taking into account the recommendations of leading international organizations for the treatment and prevention of cardiovascular diseases. The drugs used were analyzed in terms of their influence on clinical symptoms, quality of life of patients, the risk of hospitalization due to decompensation of CHF, and mortality rates. The emphasis is made on the possibilities, mechanism of action and further prospects for the use of a new class of drugs in the treatment of CHF, acting at the level of the renin-angiotensin-aldosterone system and the system of neutral endopeptidases - inhibitors of angiotensin-neprilisin receptors.

Effect of cardiac resynchronization therapy on quality of life: Role of hypertension

2018 ◽  
pp. 1-6
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Cardiac Resynchronization Therapy ◽  
Interventricular Septum ◽  
Left Ventricular ◽  
Cardiac Resynchronization ◽  
Resynchronization Therapy

Aims: To evaluate cardiac function, quality of life and role of hypertension in symptomatic heart failure in patients with Cardiac Resynchronization Therapy (CRT). Methods: 80 patients with heart failure were enrolled in our study. Among them 30 patients underwent CRT implantation (CRT group) and 50 patients received optimal medical therapy only (non-CRT group). Follow-up was carried out for 20 ± 2.828 months. Assessment of New York Hear Association (NYHA) class, QRS width, Ejection Fraction (EF), left ventricular end diastolic diameter, left ventricular end systolic diameter, interventricular septum, posterior wall thickness, degree of Mitral Regurgitation (MR) and Basic Natriuretic Peptide (BNP) level was performed at baseline and follow-up along with number of admissions and Quality of Life (QOL) assessment. Results: The baseline indices of patients in the CRT and non-CRT groups were statistically same (P>0.05). At the end of follow-up most indices showed significant improvement in the CRT group (P<0.05) except thickness of IVS and the PWT (P>0.05). The indices in the non-CRT group only showed significant improvement in EF and BNP level (P<0.05). Hypertensive patients did not show significant impact on number of admissions and QOL (P<0.05). Conclusions: Patients receiving CRT had an overall improved outcome with beneficial effects in cardiac remodeling, enhancing the left ventricular function and improving the quality of life. Hypertension was associated with poorer outcome

Sign in / Sign up

Export Citation Format

Share Document